

(43) International Publication Date
27 February 2014 (27.02.2014)

WIPO | PCT

(10) International Publication Number
WO 2014/031784 A1

(51) International Patent Classification:

C07D 333/52 (2006.01) **C07D 311/02** (2006.01)
C07C 251/84 (2006.01) **C07D 333/02** (2006.01)
C07C 251/86 (2006.01) **C07D 335/04** (2006.01)
C07D 207/00 (2006.01) **C07D 401/00** (2006.01)
C07D 209/04 (2006.01) **C07D 403/00** (2006.01)
C07D 213/00 (2006.01) **C07D 407/00** (2006.01)
C07D 215/00 (2006.01) **C07D 409/00** (2006.01)
C07D 217/00 (2006.01) **C07D 413/00** (2006.01)
C07D 233/60 (2006.01) **C07D 417/00** (2006.01)
C07D 235/02 (2006.01) **C07D 417/02** (2006.01)
C07D 249/04 (2006.01) **C07D 495/02** (2006.01)
C07D 249/18 (2006.01) **C07D 495/14** (2006.01)
C07D 261/02 (2006.01) **A61K 31/16** (2006.01)
C07D 265/00 (2006.01) **A61K 31/33** (2006.01)
C07D 307/02 (2006.01) **A61K 31/14** (2006.01)
C07D 307/78 (2006.01)

(21) International Application Number:

PCT/US2013/056052

(22) International Filing Date:

21 August 2013 (21.08.2013)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

61/692,595 23 August 2012 (23.08.2012) US
 61/702,646 18 September 2012 (18.09.2012) US

(71) Applicant: **ALIOS BIOPHARMA, INC.** [US/US]; 260 E. Grand Ave, 2nd Floor, South San Francisco, CA 94080 (US).

(72) Inventors: **WANG, Guangyi**; 5066 Millay Court, Carlsbad, CA 92008 (US). **BEIGELMAN, Leonid**; 991 East Grant Place, San Mateo, CA 94402 (US). **TRUONG, Anh**;

1349 Sanchez Ave., Burlingame, CA 94010 (US). **NA-POLITANO, Carmela**; Via Santa Teresa 49, I-37135 Verona (IT). **ANDREOTTI, Daniele**; Aptuit, Via Alessandro Fleming 4, I-CAP 37157 Verona (IT). **HE, Haiying**; 288 Fute Zhong Roadm Waigaoqiao Free, Trade Zone, Shanghai, 200131 (CN).

(74) Agent: **MILLER, Kimberly J.**; Knobbe Martens Olson & Bear LLP, 2040 Main Street, 14th Floor, Irvine, CA 92614 (US).

(81) Designated States (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

— with international search report (Art. 21(3))

(54) Title: COMPOUNDS FOR THE TREATMENT OF PARAMOXYVIRUS VIRAL INFECTIONS

(57) Abstract: Disclosed herein are new antiviral compounds, together with pharmaceutical compositions that include one or more antiviral compounds, and methods of synthesizing the same. Also disclosed herein are methods of ameliorating and/or treating a paramyxovirus viral infection with one or more small molecule compounds. Examples of paramyxovirus infection include an infection caused by human respiratory syncytial virus (RSV).